Literature DB >> 3711685

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine.

P R Johnson, S Feldman, J M Thompson, J D Mahoney, P F Wright.   

Abstract

Live attenuated, cold-adapted (ca) influenza A vaccines administered intranasally have been well characterized as safe and immunogenic, but comparative data on protective efficacy are required for further development. In this study, 59 young children were divided into the following four groups based on prior exposure to influenza A (H3N2) virus: natural infection, live ca vaccine given intranasally, inactivated vaccine given im, and no previous exposure. Virus challenge with homologous live ca vaccine occurred 12 months after vaccination or natural infection. Prior natural infection and live ca vaccine significantly reduced ca virus shedding after challenge compared with inactivated vaccine or no prior exposure to influenza A virus. Prechallenge nasal IgA, detected almost exclusively in subjects naturally infected or vaccinated with live ca virus, was associated with protection. Although inactivated vaccine failed to produce significant local IgA during the primary response, it seemed to prime for secondary local antibody responses after challenge with live ca virus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711685     DOI: 10.1093/infdis/154.1.121

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign.

Authors:  Carlos G Grijalva; Yuwei Zhu; Lone Simonsen; Marie R Griffin
Journal:  Vaccine       Date:  2010-11-02       Impact factor: 3.641

2.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 4.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

5.  The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus.

Authors:  E T Ben Ahmeida; R Jennings; M Erturk; C W Potter
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Ab and T cell epitopes of influenza A virus, knowledge and opportunities.

Authors:  Huynh-Hoa Bui; Bjoern Peters; Erika Assarsson; Innocent Mbawuike; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-02       Impact factor: 11.205

7.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

8.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 9.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.